Radiogenomic Predictors of Adverse Effects following Charged Particle Therapy.
Radiogenomic Predictors of Adverse Effects following Charged Particle Therapy.
复制标题
DOI：
10.14338/ijpt-18-00009.1
复制
发表时间：
2018
影响因子：
1.7
通讯作者：
Rosenstein BS
中科院分区：
文献类型：
--
作者：
Morton LM;Ricks-Santi L;West CML;Rosenstein BS
放射基因组学是研究与放射治疗反应相关的基因组因素。近年来，在确定与辐射后期引起的不良影响有关的遗传风险因素方面取得了进展。这些进展得到了国际放射基因组学联盟的支持，该联盟的合作研究扩大了队列规模，以增加统计能力，并努力改善放射基因组学研究的方法。已发表的研究主要报告了涉及使用外部射束放射疗法接受光子治疗的患者的研究结果。这些研究证明了我们有能力汇集国际队列，以确定与正常组织毒性风险相关的常见单核苷酸多态性。在发现与放射治疗相关的后续恶性肿瘤相关的遗传变异方面也取得了进展。随着带电粒子治疗（CPT）的使用越来越多，有必要为接受这些先进技术形式的放射治疗的患者建立队列，并创建具有相关临床数据的生物储存库。虽然一些遗传变异可能会影响光子和带电粒子的毒性和第二次恶性肿瘤风险，但由于其生物学效应的差异（包括产生的DNA损伤的复杂性），其他遗传变异可能对辐射方式具有特异性，这是合理的。认识到形成CPT治疗的放射基因组学研究的患者队列是一个高度优先事项，正在努力建立涉及质子和/或碳离子治疗癌症患者的机构以及联盟的合作，包括质子合作组，粒子治疗合作组和儿科质子联盟登记处。这些重要的放射基因组CPT倡议需要在国际上扩大，以建立从放射基因组学联盟和流行病学家调查正常组织毒性和第二癌症风险获得的经验。
Radiogenomics is the study of genomic factors that are associated with response to radiation therapy. In recent years, progress has been made toward identifying genetic risk factors linked with late radiation-induced adverse effects. These advances have been underpinned by the establishment of an international Radiogenomics Consortium with collaborative studies that expand cohort sizes to increase statistical power and efforts to improve methodologic approaches for radiogenomic research. Published studies have predominantly reported the results of research involving patients treated with photons using external beam radiation therapy. These studies demonstrate our ability to pool international cohorts to identify common single nucleotide polymorphisms associated with risk for developing normal tissue toxicities. Progress has also been achieved toward the discovery of genetic variants associated with radiation therapy–related subsequent malignancies. With the increasing use of charged particle therapy (CPT), there is a need to establish cohorts for patients treated with these advanced technology forms of radiation therapy and to create biorepositories with linked clinical data. While some genetic variants are likely to impact toxicity and second malignancy risks for both photons and charged particles, it is plausible that others may be specific to the radiation modality due to differences in their biological effects, including the complexity of DNA damage produced. In recognition that the formation of patient cohorts treated with CPT for radiogenomic studies is a high priority, efforts are underway to establish collaborations involving institutions treating cancer patients with protons and/or carbon ions as well as consortia, including the Proton Collaborative Group, the Particle Therapy Cooperative Group, and the Pediatric Proton Consortium Registry. These important radiogenomic CPT initiatives need to be expanded internationally to build on experience gained from the Radiogenomics Consortium and epidemiologists investigating normal tissue toxicities and second cancer risk.